U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

2014
503
Substance Class Protein
Created
by admin
on Mon Mar 31 20:44:42 GMT 2025
Edited
by admin
on Mon Mar 31 20:44:42 GMT 2025
Protein Type BISPECIFIC ANTIBODY
Protein Sub Type SCFV
Sequence Origin MOUSE
Sequence Type COMPLETE
Record UNII
4FR53SIF3A
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BLINATUMOMAB
DASH   INN   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
BLINCYTO
Preferred Name English
AMG103
Code English
blinatumomab [INN]
Common Name English
BLINATUMOMAB [MI]
Common Name English
AMG-103
Code English
MT103
Code English
BLINATUMOMAB [USAN]
Common Name English
BLINATUMOMAB [JAN]
Common Name English
Blinatumomab [WHO-DD]
Common Name English
MT-103
Code English
IMMUNOGLOBULIN, ANTI-(HUMAN CD19 (ANTIGEN)) (SINGLE-CHAIN) FUSION PROTEIN WITH IMMUNOGLOBULIN, ANTI-(HUMAN CD3 (ANTIGEN)) (CLONE 1 SINGLE-CHAIN)
Common Name English
BLINATUMOMAB [VANDF]
Common Name English
MEDI-538
Code English
BLINATUMOMAB [PURPLE BOOK CDER]
Common Name English
MEDI538
Code English
Classification Tree Code System Code
NCI_THESAURUS C129822
Created by admin on Mon Mar 31 20:44:42 GMT 2025 , Edited by admin on Mon Mar 31 20:44:42 GMT 2025
NCI_THESAURUS C112889
Created by admin on Mon Mar 31 20:44:42 GMT 2025 , Edited by admin on Mon Mar 31 20:44:42 GMT 2025
WHO-ATC L01XC19
Created by admin on Mon Mar 31 20:44:42 GMT 2025 , Edited by admin on Mon Mar 31 20:44:42 GMT 2025
FDA ORPHAN DRUG 203405
Created by admin on Mon Mar 31 20:44:42 GMT 2025 , Edited by admin on Mon Mar 31 20:44:42 GMT 2025
NDF-RT N0000191421
Created by admin on Mon Mar 31 20:44:42 GMT 2025 , Edited by admin on Mon Mar 31 20:44:42 GMT 2025
EU-Orphan Drug EU/3/09/650
Created by admin on Mon Mar 31 20:44:42 GMT 2025 , Edited by admin on Mon Mar 31 20:44:42 GMT 2025
EMA ASSESSMENT REPORTS BLINCYTO (AUTHORIZED: PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA)
Created by admin on Mon Mar 31 20:44:42 GMT 2025 , Edited by admin on Mon Mar 31 20:44:42 GMT 2025
FDA ORPHAN DRUG 255707
Created by admin on Mon Mar 31 20:44:42 GMT 2025 , Edited by admin on Mon Mar 31 20:44:42 GMT 2025
FDA ORPHAN DRUG 261808
Created by admin on Mon Mar 31 20:44:42 GMT 2025 , Edited by admin on Mon Mar 31 20:44:42 GMT 2025
NCI_THESAURUS C112883
Created by admin on Mon Mar 31 20:44:42 GMT 2025 , Edited by admin on Mon Mar 31 20:44:42 GMT 2025
NCI_THESAURUS C1454
Created by admin on Mon Mar 31 20:44:42 GMT 2025 , Edited by admin on Mon Mar 31 20:44:42 GMT 2025
FDA ORPHAN DRUG 585917
Created by admin on Mon Mar 31 20:44:42 GMT 2025 , Edited by admin on Mon Mar 31 20:44:42 GMT 2025
FDA ORPHAN DRUG 261908
Created by admin on Mon Mar 31 20:44:42 GMT 2025 , Edited by admin on Mon Mar 31 20:44:42 GMT 2025
FDA ORPHAN DRUG 261708
Created by admin on Mon Mar 31 20:44:42 GMT 2025 , Edited by admin on Mon Mar 31 20:44:42 GMT 2025
Code System Code Type Description
NDF-RT
N0000191422
Created by admin on Mon Mar 31 20:44:42 GMT 2025 , Edited by admin on Mon Mar 31 20:44:42 GMT 2025
PRIMARY CD19-directed Antibody Interactions [MoA]
MERCK INDEX
m11822
Created by admin on Mon Mar 31 20:44:42 GMT 2025 , Edited by admin on Mon Mar 31 20:44:42 GMT 2025
PRIMARY
ChEMBL
CHEMBL1742992
Created by admin on Mon Mar 31 20:44:42 GMT 2025 , Edited by admin on Mon Mar 31 20:44:42 GMT 2025
PRIMARY
NCI_THESAURUS
C62528
Created by admin on Mon Mar 31 20:44:42 GMT 2025 , Edited by admin on Mon Mar 31 20:44:42 GMT 2025
PRIMARY
DAILYMED
4FR53SIF3A
Created by admin on Mon Mar 31 20:44:42 GMT 2025 , Edited by admin on Mon Mar 31 20:44:42 GMT 2025
PRIMARY
RXCUI
1597258
Created by admin on Mon Mar 31 20:44:42 GMT 2025 , Edited by admin on Mon Mar 31 20:44:42 GMT 2025
PRIMARY RxNorm
CAS
853426-35-4
Created by admin on Mon Mar 31 20:44:42 GMT 2025 , Edited by admin on Mon Mar 31 20:44:42 GMT 2025
PRIMARY
FDA UNII
4FR53SIF3A
Created by admin on Mon Mar 31 20:44:42 GMT 2025 , Edited by admin on Mon Mar 31 20:44:42 GMT 2025
PRIMARY
INN
9028
Created by admin on Mon Mar 31 20:44:42 GMT 2025 , Edited by admin on Mon Mar 31 20:44:42 GMT 2025
PRIMARY
USAN
TT-64
Created by admin on Mon Mar 31 20:44:42 GMT 2025 , Edited by admin on Mon Mar 31 20:44:42 GMT 2025
PRIMARY
SMS_ID
100000128395
Created by admin on Mon Mar 31 20:44:42 GMT 2025 , Edited by admin on Mon Mar 31 20:44:42 GMT 2025
PRIMARY
EVMPD
SUB35403
Created by admin on Mon Mar 31 20:44:42 GMT 2025 , Edited by admin on Mon Mar 31 20:44:42 GMT 2025
PRIMARY
WIKIPEDIA
BLINATUMOMAB
Created by admin on Mon Mar 31 20:44:42 GMT 2025 , Edited by admin on Mon Mar 31 20:44:42 GMT 2025
PRIMARY
DRUG CENTRAL
4915
Created by admin on Mon Mar 31 20:44:42 GMT 2025 , Edited by admin on Mon Mar 31 20:44:42 GMT 2025
PRIMARY
NDF-RT
N0000175618
Created by admin on Mon Mar 31 20:44:42 GMT 2025 , Edited by admin on Mon Mar 31 20:44:42 GMT 2025
PRIMARY CD3 Receptor Agonists [MoA]
IUPHAR
7384
Created by admin on Mon Mar 31 20:44:42 GMT 2025 , Edited by admin on Mon Mar 31 20:44:42 GMT 2025
PRIMARY
LACTMED
Blinatumomab
Created by admin on Mon Mar 31 20:44:42 GMT 2025 , Edited by admin on Mon Mar 31 20:44:42 GMT 2025
PRIMARY
DRUG BANK
DB09052
Created by admin on Mon Mar 31 20:44:42 GMT 2025 , Edited by admin on Mon Mar 31 20:44:42 GMT 2025
PRIMARY
Related Record Type Details
B-LYMPHOCYTE ANTIGEN CD19
TARGET->LIGAND
CD3
CD3
TARGET -> ACTIVATOR
Related Record Type Details
BLINATUMOMAB
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC ROUTE OF ADMINISTRATION
PHARMACOKINETIC
Molecular Formula CHEMICAL
Volume of Distribution PHARMACOKINETIC ROUTE OF ADMINISTRATION
PHARMACOKINETIC
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966